Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.
Journal
Pharmacogenetics and genomics
ISSN: 1744-6880
Titre abrégé: Pharmacogenet Genomics
Pays: United States
ID NLM: 101231005
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
The main objective of this study was to evaluate the effect of CYP2B6 and CYP3A4 polymorphisms on the virological and immunologic responses of HIV patients. A total of 153 HIV-positive patients were enlisted for the study. Viral load and median CD4 T cell counts were evaluated at baseline and month 6 (M6). Samples were identified using TaqMan genotyping assays. The AG in CYP2B6 rs2279343 was associated with VLS compared to homozygous AA. In the dominant model, the AG/GG genotypes were associated with VLS compared to the AA genotype. Moreover, in overdominant model, the AG genotype was associated with VLS compared to AA/GG. Regarding immunological response, only the AG in SNP rs2279343 CYP2B6 was associated with an increase in CD4 cell count between baseline and M6. In CYP2B6 rs3745274, the CD4 cell count at M6 was higher than that of baseline for GG carriers and for GT carriers. In CYP3A4 rs2740574, the TC carriers showed a higher median CD4 count at M6 compared to that of the baseline count, as well as for CC carriers. The best genotypes combination associated with CD4 cell count improvement were AA/AG in SNP rs2279343 and GG/GT in SNP rs3745274. Our findings support the fact that CYP2B6 rs2279343 could help in the prediction of VLS and both SNPs rs3745274 and rs2279343 in CYP2B6 and CYP3A4 rs2740574 were associated with immune recovery in Malian HIV-positive patients.
Identifiants
pubmed: 35852913
doi: 10.1097/FPC.0000000000000477
pii: 01213011-202208000-00001
pmc: PMC7613628
mid: EMS146401
doi:
Substances chimiques
Alkynes
0
Anti-HIV Agents
0
Benzoxazines
0
Cyclopropanes
0
Cytochrome P-450 CYP2B6 Inhibitors
0
CYP2B6 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2B6
EC 1.14.14.1
Cytochrome P-450 CYP3A
EC 1.14.14.1
CYP3A4 protein, human
EC 1.14.14.55
efavirenz
JE6H2O27P8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-225Subventions
Organisme : European & Developing Countries Clinical Trials Partnership
ID : EDCTP_TMA2016CDF-1566
Pays : Netherlands
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
UNAIDS. Jt United Nations Program HIV/AIDS Report. 2019. https//www.unaids.org/ en/resources/documents/2019/2019-UNAIDS-data .
Bordin Andriguetti N, Van Schalkwyk HK, Barratt DT, Tucci J, Pumuye P, Somogyi AA. Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clin Transl Sci. 2021; 14:2521–2531.
Rzeszutek M, Gruszczyńska E, Pięta M, Malinowska P. HIV/AIDS stigma and psychological well-being after 40 years of HIV/AIDS: a systematic review and meta-analysis. Eur J Psychotraumatol. 2021; 12:1990527.
Bengtson AM, Pence BW, Eaton EF, Edwards JK, Eron JJ, Mathews WC, et al. Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther. 2018; 23:363–372.
Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization’s global antiretroviral guidance. J Int AIDS Soc. 2013; 16:18757.
Mugusi S, Ngaimisi E, Janabi M, Mugusi F, Minzi O, Aris E, et al. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. Eur J Clin Pharmacol. 2018; 74:1405–1415.
Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, et al.; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015; 60:1860–1863.
Marzolini C, Chave JP, Telenti A, Brenas-Chinchon L, Biollaz J. Impaired absorption of rifabutin by concomitant administration of didanosine. AIDS. 2001; 15:2203–2204.
Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005; 41:1648–1653.
Shastry BS. Pharmacogenetics and the concept of individualized medicine. Pharmacogenomics J. 2006; 6:16–21.
Mitchell AA, Chakravarti A, Cutler DJ. On the probability that a novel variant is a disease-causing mutation. Genome Res. 2005; 15:960–966.
Navarro SL, Saracino MR, Makar KW, Thomas SS, Li L, Zheng Y, et al. Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases. J Nutrigenet Nutrigenomics. 2011; 4:110–118.
Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, et al.; CACT0810 group. HIV-1 subtype B/B’ and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. J Acquir Immune Defic Syndr. 2015; 68:289–297.
Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, et al. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults. Br J Clin Pharmacol. 2012; 74:1005–1012.
Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, et al. Effect of CYP2B6 gene polymorphisms on efavirenz plasma concentrations in Chinese patients with HIV infection. PLoS One. 2015; 10:e0130583.
de Almeida TB, de Azevedo MCVM, Pinto JFDC, Ferry FRA, da Silva GAR, de Castro IJ, et al. Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. J Antimicrob Chemother. 2018; 73:2460–2467.
Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003; 306:287–300.
Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, Nhachi C, Masimirembwa C. High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008; 64:357–365.
Reay R, Dandara C, Viljoen M, Rheeders M. CYP2B6 haplotype predicts Efavirenz plasma concentration in black South African HIV-1-infected children: a longitudinal pediatric pharmacogenomic study. OMICS. 2017; 21:465–473.
Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit. 2012; 34:153–159.
Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and Efavirenz-containing antiretroviral therapy. Clin Pharmacol Ther. 2019; 106:726–733.
Desta Z, El-Boraie A, Gong L, Somogyi AA, Lauschke VM, Dandara C, et al. PharmVar GeneFocus: CYP2B6. Clin Pharmacol Ther. 2021; 110:82–97.
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, et al.; Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin Infect Dis. 2006; 42:401–407.
Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, et al. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. Br J Clin Pharmacol. 2015; 80:146–156.
Kassogue Y, Diakite B, Kassogue O, Konate I, Tamboura K, Diarra Z, et al. Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: implication for pharmacogenetics. Medicine (Baltimore). 2021; 100:e26614.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22:1928–1929.
Waxman DJ, Ko A, Walsh C. Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem. 1983; 258:11937–11947.
Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993; 7:69–75.
Dehal SS, Kupfer D. Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Dual pathways involving novel ortho ring-hydroxylation by CYP2B. Drug Metab Dispos. 1994; 22:937–946.
Ekins S, Wrighton SA. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab Rev. 1999; 31:719–754.
Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001; 11:399–415.
Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, et al. CYP2B6 genetic polymorphisms, depression, and viral suppression in adults living with HIV initiating Efavirenz-containing antiretroviral therapy regimens in Uganda: pooled analysis of two prospective studies. AIDS Res Hum Retroviruses. 2018; 34:982–992.
Haas DW, Severe P, Jean Juste MA, Pape JW, Fitzgerald DW. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. J Antimicrob Chemother. 2014; 69:2187–2190.
Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS clinical trials group study. J Infect Dis. 2010; 202:717–722.
Langmia IM, Just KS, Yamoune S, Brockmöller J, Masimirembwa C, Stingl JC. CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy. Front Genet. 2021; 12:692234.
Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007; 81:557–566.
Oluka MN, Okalebo FA, Guantai AN, McClelland RS, Graham SM. Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study. AIDS Res Ther. 2015; 12:10.
Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003; 42:299–305.
Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Asghar M, Homann MV, et al. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017; 16:267.